23ANDME HOLDING CO -CLASS A (ME) Stock Price, Forecast & Analysis
NASDAQ:ME • US90138Q3065
ME Key Statistics, Chart & Performance
The current stock price of ME is 0.6063 USD. In the past month the price decreased by -72.44%. In the past year, price decreased by -94.3%.
ME Technical Analysis
ME Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ME. ME scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ME Financial Highlights
Over the last trailing twelve months ME reported a non-GAAP Earnings per Share(EPS) of -13.2. The EPS decreased by -29.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -138.01% | ||
| ROE | -545.25% | ||
| Debt/Equity | 0 |
ME Forecast & Estimates
9 analysts have analysed ME and the average price target is 2.12 USD. This implies a price increase of 249.93% is expected in the next year compared to the current price of 0.6063.
For the next year, analysts expect an EPS growth of -329.17% and a revenue growth 22.44% for ME
ME Ownership
ME Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.59 | 98.152B | ||
| CI | THE CIGNA GROUP | 8.97 | 75.329B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 98.8 | 24.421B | ||
| LH | LABCORP HOLDINGS INC | 15.69 | 23.418B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.25 | 22.519B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.706B | ||
| DVA | DAVITA INC | 11.4 | 10.1B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 29.97 | 7.358B | ||
| CHE | CHEMED CORP | 18.52 | 6.685B | ||
| OPCH | OPTION CARE HEALTH INC | 18.72 | 5.66B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ME
Company Profile
23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California and currently employs 560 full-time employees. The company went IPO on 2020-10-06. The firm operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Company Info
23ANDME HOLDING CO -CLASS A
349 Oyster Point Boulevard
South San Francisco CALIFORNIA US
CEO: Josh Bayliss
Employees: 560
Phone: 16509386300
23ANDME HOLDING CO -CLASS A / ME FAQ
Can you describe the business of 23ANDME HOLDING CO -CLASS A?
23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California and currently employs 560 full-time employees. The company went IPO on 2020-10-06. The firm operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Can you provide the latest stock price for 23ANDME HOLDING CO -CLASS A?
The current stock price of ME is 0.6063 USD. The price decreased by -21.26% in the last trading session.
What is the dividend status of 23ANDME HOLDING CO -CLASS A?
ME does not pay a dividend.
What is the ChartMill technical and fundamental rating of ME stock?
ME has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about 23ANDME HOLDING CO -CLASS A (ME) stock?
9 analysts have analysed ME and the average price target is 2.12 USD. This implies a price increase of 249.93% is expected in the next year compared to the current price of 0.6063.
Should I buy ME stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ME.
Can you provide the growth outlook for 23ANDME HOLDING CO -CLASS A?
The Revenue of 23ANDME HOLDING CO -CLASS A (ME) is expected to grow by 22.44% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.